Table 2.
Drug resistance and mutation sites in 14 patients.
| Potential Low-Level Resistance | Low-Level Resistance | Intermediate Resistance | High-Level Resistance | ||||||
| Drug Classification | Number of cases | Mutations | Number of cases | Mutations | Number of cases | Mutations | Number of cases | Mutations | |
| Protease Inhibitors | atazanavir/r (ATV/r) | 2 | M46L|M46I | 1 | V82A | ||||
| fosamprenavir/r (FPV/r) | 5 | L33F|V82A|M46L|M46I | |||||||
| indinavir/r (IDV/r) | 2 | M46L|M46I | 1 | V82A | |||||
| lopinavir/r (LPV/r) | 2 | M46L|M46I | 1 | V82A | |||||
| saquinavir/r (SQV/r) | 2 | V82A|M46I | |||||||
| nelfinavir (NFV) | 2 | V82A|M46L | 2 | V82A|M46I | |||||
| tipranavir/r (TPV/r) | 2 | L33F|Q58E | |||||||
| Nucleoside Reverse Transcriptase Inhibitors | lamivudine (3TC) | 1 | K65R | ||||||
| abacavir (ABC) | 1 | K65R | |||||||
| zidovudine (AZT) | 1 | K219Q | 1 | T215A | |||||
| stavudine (D4T) | 2 | V75VI|K219Q | 1 | T215A | 1 | K65R | |||
| didanosine (DDI) | 1 | V75VI | 1 | K65R | |||||
| emtricitabine (FTC) | 1 | K65R | |||||||
| tenofovir (TDF) | 1 | K65R | |||||||
| Non-nucleoside Reverse Transcriptase Inhibitors | efavirenz (EFV) | 2 | V179D | 1 | A98G | 1 | Y181C+G190S | ||
| etravirine (ETR) | 3 | A98G|V106I|V179D | 1 | Y181C+G190S | |||||
| nevirapine (NVP) | 3 | V179E|V106I|V179D | 1 | A98G | 1 | Y181C+G190S | |||
| rilpivirine (RPV) | 2 | V106I|V179D | 1 | A98G | 1 | Y181C+G190S | |||